Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Medisun Forms China Stem Cell JV with Belgium's Cardio3

publication date: Jun 16, 2014
Medisun International, a Hong Kong startup that plans to develop a portfolio of regenerative treatments for China, formed a JV with Cardio3 BioSciences of Belgium. The JV will hold China rights to Cardio3’s stem cell treatment, C-Cure®. A clinical-stage product for congestive heart failure, C-Cure is based on stem cells that are guided toward becoming heart cells. Medisun will make a $38 million investment in Cardio3, giving it an 8% stake in the company. In addition, Medisun has committed at least $27 million to the China joint venture. More details....

Stock Symbols: (PA: CARD; BX: CARD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital